LifeCycle Pharma A/S - Total number of voting rights and size of share capital in LifeCycle Pharma A/S as of November 30, 2010

Company Announcement no. 26/2010

To: NASDAQ OMX Copenhagen A/S                                       Hørsholm,
Denmark, November 30, 2010 
		
LifeCycle Pharma A/S - Total number of voting rights and size of share capital
in LifeCycle Pharma A/S as of November 30, 2010 

In accordance with Section 6 of the Danish Executive Order on Issuers'
Disclosure Obligations, LifeCycle Pharma A/S is required to publish the total
number of voting rights and the size of the share capital in LifeCycle Pharma
A/S at the end of each calendar month where there has been a change.  The share
capital in LifeCycle Pharma A/S consists of one class of shares and as of 30
November 2010 the share capital amounts to DKK 452,542,480 divided into
452,542,480 shares of DKK 1 each and 452,542,480 votes. 
 
For more information, please contact: 

LifeCycle Pharma A/S

William J. Polvino, President and CEO	Johnny Stilou, CFO
Mobile: +1 917 647 9107	                  Mobile: +45 20 55 38 52
Email: WJP@lcpharma.com	                  Email: JST@lcpharma.com 


Forward-looking statement disclaimer
This press release contains certain forward-looking statements, including
statements about the Company's business and its shares. Such forward-looking
statements are based on data, assumptions and estimates that the Company
considers to be reasonable. They are subject to numerous risks and
uncertainties, including matters not yet known to the Company or not currently
considered material by the Company, and there can be no assurance that
anticipated events will occur or that the objectives set out will actually be
achieved.  Important factors that could cause actual results to differ
materially from the results anticipated in forward-looking statements include,
among others, market conditions and the price of the Company's shares,
completion of and the actual outcome of the Company's ongoing Phase III
clinical studies of LCP-Tacro™, as well as changes in pharmaceutical industry
regulation and, in particular, regulatory approval of pharmaceutical drugs, as
well as the other risk factors the Company has included in its public
disclosures.